July 30, 2021 7:51am

Wait until next week as earnings flood the week and summer seasonality sets in  

Pre-open indications: 3 SELLs: EDIT, NTLA, ALNY; 3 BUYs: CRSP, PSTI, CLLS and 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

There is no breadline for fact and numbers-based share pricing intelligence!

Dow futures are DOWN -0.31% (-107 points), S&P futures are DOWN -0.63% (-28 points) and NASDAQ futures are DOWN -1.01% (-152 points)

 

Stock market futures fell on Friday pointing to a lower open,

European stocks retreated after closing the previous session at all-time highs,

Asia-Pacific stocks declined again, heading for their worst month since March 2020, as volatile trading continued.

 

Data Docket: personal consumption expenditures price index, Friday morning at 8:30 a.m. ET.

 

Henry’omics:

Yesterday, the Nasdaq underperformed with only a 0.1% gain …

Thursday’s positive session came despite a government report that showed U.S. Q2 gross domestic product accelerated 6.5% on an annualized basis, considerably less than the 8.4% estimate.

 

Thursday’s evening’s recap: “in the blink of an eye or a mid-day dive, the oversold became the overbought with low or negligible volume leaving sentiment staring into a corner:” … https://www.regmedinvestors.com/articles/12026

  • The Nasdaq closed UP +15.68 points (+0.11%);
  • The IBB closed down -0.61% and XBI closed down -1.66%
  • Sector volume was LOW with 0 of the 8-upside having higher than the 3-month average volume with very LOW volume of 1 of 23-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.61 points or -3.33% at 17.70
  • Thursday’s percentage (%) of the 8-upside were +0.29% (EDIT) to +1.73% (MESO) while the 23-downside ranges from -0.15% (ALNY) to -4.26% (RGNX);

Week to date: 3 negative and 1 positive closes

Q3/21: July, 6 positive, 1 holiday and 14 negative closes

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?

Biostage (BSTG) closed flat again on Thursday with 1 share traded after Wednesday’s flat with 450 shares traded after on Tuesday’s down -$0.06 to $1.65 on Monday with 406 shares traded after being flat, Friday and Thursday with 200 shares traded (each session).

Question#1: WHAT is the status of the $404,221.00 PPP Loan? Referencing the loan agreement, “In the event that any portion of the PPP Loan is not forgiven in accordance with the PPP, following a six-month deferred period that ends November 4, 2020, the Company will be required to pay the Bank monthly payments of principal and interest to repay the PPP Loan in full on or before the maturity date.”

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

BUY:

CRISPR Therapeutics (CRSP) closed down -$0.75 to $119.00 after Wednesday’s +$2.32 to $119.75, Tuesday’s -$1.79 to $117.43, Monday’s -$3.05 to $119.11 and last Friday’s -$2.50 to $122.27 and has a positive pre-open indication of +4.25 or +3.57%. CRSP reported net income and a solid cash position on Thursday.

Pluristem (PSTI) closed down -$0.07 to $3.34 after Wednesday’s $3.41, Tuesday’s $3.24, Monday’s $3.32 and last Friday’s $3.43 with a positive +$0.10 or +2.99% aftermarket indication.

 

BUY from SELL into Strength:

Cellectis SA (CLLS) closed down -$0.42 to $13.28 after Wednesday’s $13.70, Tuesday’s $12.99, Monday’s $13.17 and last Friday’s $13.75 with a positive +$0.06 or +0.45% pre-market indication.

 

SELL:

Editas Medicine (EDIT) closed up +$0.12 to $41.90 after Wednesday’s +$2.51 to $41.78, Tuesday’s -$0.58 to $39.27, Monday’s $39.85 and last Friday’s $40.84 with a negative -$0.54 or -.29% pre-market indication. Earnings release next week on 8/4

 

Maintaining SELL:

Intellia Therapeutics (NTLA) closed up =$0.85 to $137.02 after Wednesday’s +$3.80 to $136.17, Tuesday’s -$1.63 to $132.37, Monday’s $134.00 and last Friday’s $137.71 with a negative -$1.01 or -0.74% pre-market indication

  • NTLA is projected to report earnings of -$0.61 per share, which would represent no growth from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $12.03 million, down 26.03% from the year-ago period. NTLA's full-year Zacks Consensus Estimates are calling for earnings of -$2.56 per share and revenue of $36.32 million. These results would represent year-over-year changes of -6.67% and -37.37%.

Alnylam Pharmaceuticals (ALNY) closed down -$0.27 to $181.83 after Wednesday’s +$5.51 to $182.10, Tuesday’s -$1.52 to $176.59, Monday’s $178.11 and last Friday’s $182.41 with a negative -$0.63 or -0.35% aftermarket indication

  • ALNY reports earnings on Tuesday, 8/3 and is expected to post a quarterly loss of -$1.57 per share in its upcoming report, which represents a year-over-year change of -0.6%. Revenues are expected to be $199.77 million, up 92.2% from the year-ago quarter. < Zacks Consensus Estimates>

 

Maintaining SELL:

The BOTTOM LINE: I used to think negativity was a state of mind. Now, having watched for long enough, I come to realize negativity can be a character trait … yesterday (Thursday) and today’s (Friday’s) big question is what will be sustained in share pricing?

Volatility is still front-and-center in the sector …

  • Thursday, the IBB closed down -0.61% and XBI closed down -1.66%
  • Wednesday, the IBB closed up +2.81% and XBI closed up +3.50%;
  • Tuesday, the IBB closed down -0.81% and the IBB closed down -1%
  • Monday, the IBB closed down -1.89% and XBI closed down -1.81%
  • Friday, the IBB closed up +0.88% and XBI closed down -1.14%

The cell and gene therapy sector is still confusing as sentiment rages and fades, volume slithers, momentum is burped and usurped as fundamentals seem ignored.

uniQure NV (QURE) released net income earnings’ release. More Q2 earnings LPS (loss-per-share) release date: Ultragenyx Pharmaceuticals (RARE) on 8/2; Sage Therapeutics (SAGE), Global Blood Therapeutics (GBT) and Alnylam Pharmaceuticals (ALNY) release “earnings” on 8/3 followed by Vericel (VCEL), MiMedx (MDXG), AxoGen (AXGN) and Editas Medicine (EDIT) on Wednesday, 8/4, Brainstorm Cell Therapeutics (BCLI) on 8/5 and Athersys ATHX) on 8/9 – so far.

Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.

Risk is no doubt increasing as we head into the troublesome August and September months

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.